GAITHERSBURG, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announces the appointment of Mark Avagliano as Chief Business Officer. The news comes as Georgiamune closes out 2024 after having initiated three assets into clinical trials. With Phase 2 testing ambitions set for 2025 across the three clinical assets in both cancer and autoimmune diseases (GIM-122, GIM-531 and GIM-407), Avagliano’s combination of business acumen and sector expertise will further empower the company to meet these pivotal milestones while ensuring that its robust earlier stage pipeline progresses through development.
Here is the original post:
Georgiamune Appoints Biopharma Veteran Mark Avagliano as Chief Business Officer to Drive Growth